Biomarkers of cardiovascular diseases
Authors:
- Kristina SavićKSKristina Savić
- Sonja ZafirovićSZSonja Zafirović
- Ivana ResanovićIRIvana Resanović
- Emina SudarESEmina Sudar
- Vera Maravić-StojkovićVMVera Maravić-Stojković
- Biljana PutnikovićBPBiljana Putniković
- Esma R. IsenovićEIEsma R. Isenović
- 1 January 2013
- journal article
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Medicinska istrazivanja
- Vol. 47 (2) , 11-19
Abstract
Biomarkers are indicators of normal biological processes, pathogenic processes or pharmacologic responses to therapeutic interventions. Interleukin-6 (IL - 6) is a biomarker whose synthesis could be activated by various stimuli, such as interferon-g (IFN - g), tumor necrosis factor (TNF) and/or interleukin - 1 (IL - 1). IL - 6 achieves its effects through the IL-6 receptor (IL - 6R). It has been shown that transgenic mice, which have induced expression of IL - 6 and IL - 6R develop myocardial hypertrophy. In myocardial hypertrophy, an important role is played by a newly discovered cardiotrophin-1, a member of the IL - 6 family. The activity of IL - 6 is associated with the development of abdominal aortic aneurysm (AAA); in fact, it has been shown that the concentration of IL - 6 positively correlates with AAA diameters. C-reactive protein (CRP) is one of the biomarkers of cardiovascular diseases. Local production of CRP by the smooth muscular and endothelial cells of the vessel leads to the development of atherosclerosis to a large extent. Oxidized low-density lipoprotein (ox - LDL) also has an important role in the development of atherosclerosis. After penetrating the intima of the vessel, ox - LDL induces monocyte collection, i.e. monocytes are translated into macrophages that bind ox - LDL. Having filled the macrophages with ox - LDL, the signals of cell death are activated, which leads to the creation of foamy cells that make up the initial part of the atherosclerotic plaque. New knowledge about the mechanism of action and the role of biomarkers in the development of cardiovascular diseases will certainly provide an opportunity to prevent the onset of these disorders, as well as an adequate therapy in the treatment of cardiovascular diseases, which is one of the main goals of intensive research in the field of biomarkers.Keywords
Funding Information
- Ministry of Education, Science and Technological Development of the Republic of Serbia (173033)
This publication has 62 references indexed in Scilit:
- Fluid-Phase Pinocytosis of Native Low Density Lipoprotein Promotes Murine M-CSF Differentiated Macrophage Foam Cell FormationPLOS ONE, 2013
- Assessing salivary C-reactive protein: Longitudinal associations with systemic inflammation and cardiovascular disease risk in women exposed to intimate partner violenceBrain, Behavior, and Immunity, 2012
- Regulation of eNOS in Caveolae2012
- Recognition and functional activation of the human IgA receptor (FcαRI) by C-reactive proteinProceedings of the National Academy of Sciences, 2011
- Supression of hemin-mediated oxidation of low-density lipoprotein and subsequent endothelial reactions by hydrogen sulfide (HS)Free Radical Biology and Medicine, 2009
- Phosphorylation of Endothelial Nitric-oxide Synthase Regulates Superoxide Generation from the EnzymeJournal of Biological Chemistry, 2008
- Endogenous Nitric Oxide Synthesis Inhibitor Asymmetric Dimethyl l -Arginine Accelerates Endothelial Cell SenescenceArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in endothelial cells by nitric oxide deficiencyAmerican Journal of Physiology-Renal Physiology, 2004
- Associations among oxidized low-density lipoprotein antibody, C-reactive protein, interleukin-6, and circulating cell adhesion molecules in patients with unstable angina pectorisThe American Journal of Cardiology, 2004
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001